Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences

JAMA: The Journal of the American Medical Association

Volumn 269, Issue 12, 1993, Pages 1513-1518

  Honig, Peter K ^a,c   Wortham, Dale C ^b   Zamani, Kaveh ^a   Conner, Dale P ^a   Mullin, James C ^b   Cantilena, Louis R ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; KETOCONAZOLE; TERFENADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; ELECTROCARDIOGRAPHY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART REPOLARIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL;

ADULT; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; HEART; HUMAN; KETOCONAZOLE; MALE; PROSPECTIVE STUDIES; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TERFENADINE;

EID: 0027468346     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1993.03500120051025     Document Type: Article

References (28)

1. Simonsen L. What are pharmacists dispensing most often? Pharm Times. April 1991:57-70.
2. IMS America Ltd. 1992 National Prescription Audit. Plymouth Meeting, Pa: IMS America Ltd; 1992.
3. Garteiz DA, Hook RH, Walker BJ, Okerholm RA. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung. 1982;32:1185-1190.
4. Chen Y, Gillis RA, Woosley RL. Block of delayed rectifier current, Ik, by terfenadine in cat ventricular myocytes. J Am Coll Cardiol. 1991;17: 140. Abstract.
5. Pulmonary-Allergy Drugs Advisory Committee. Proceedings of the Pulmonary-Allergy Drugs Advisory Committee. Rockville, Md: Food and Drug Administration, Public Health Service, US Dept of Health and Human Services; 1990.
6. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther. 1992;52:231-238.
7. Food and Drug Administration. Ketoconazole labeling revised. FDA Drug Bull. August 1984;14: 2.
8. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264:2788-2790.
9. Marion Merrell Dow Inc. Important Drug Warning. Cincinnati, Ohio: Marion Merrell Dow Inc; August 6, 1990.
10. Food and Drug Administration. Adverse Reaction Report. Rockville, Md: Division of Epidemiology and Surveillance, Center for Drug Evaluation and Research, Food and Drug Administration; June 5, 1992.
11. Coutant JE, Westmark PA, Nardella PA, Walter SM, Okerholm RA. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1991;570:139-148.
12. Bazett HC. An analysis of the times relations of electrocardiograms. Heart. 1920;7:353-370.
13. Bethea RM, Duran BS, Boullion TL. Statistical Methods for Engineers and Scientists. 2nd ed. New York, NY: Marcel Dekker Inc; 1985.
14. Matthews DR, McNutt B, Okerholm R, Flicker M, McBride G. Torsades de pointes occurring in association with terfenadine use. JAMA. 1991;266: 2375-2376.
15. Hume AL, Kerkering TM. Ketoconazole. Drug Intell Pharm. 1983;17:169-174.
16. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983;71:1495-1499.
17. Bennett JE. Antifungal agents. In: Gilman AG, Rail TW, Nies AS, Taylor P. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 8th ed. Elmsford, NY: Pergamon Press Inc; 1990.
18. Hunt CM, Watkins PB, Saenger P, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther. 1992; 51:18-23.
19. Algra A, Tijssen JGP, Roelandt JRTC, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation. 1991;83:1888-1894.
20. Food and Drug Administration. Computerized Online Medicaid Pharmaceutical and Surveillance System (COMPASS). Health Information Designs. Rockville, Md: Division of Epidemiology and Surveillance, Center for Drug Evaluation and Research, Food and Drug Administration; 1992.
21. Safety of terfenadine and astemizole. Med Lett Drugs Ther. 1992;34:9-10.
22. Sanford JP. Drug interactions with antifungals, antivirals, and other anti-infectives. J Crit Illness. 1992;7:605-612.
23. Guttendorf RJ, Wedlund PJ. Genetic aspects of drug disposition and therapeutics. J Clin Pharmacol. 1992;32:107-117.
24. Danan G, Descatoire V, Pessayre D. Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P450. J Pharmacol Exp Ther. 1981;218:509-515.
25. Alvarez J, Montero M, Garcia-Sancho J. High affinity inhibition of Ca2+-dependent channels by cytochrome P-450 inhibitors. J Biol Chem. 1992; 267:11789-11793.
26. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med. 1990;89:235-238.
27. Marion Merrell Dow Inc. Important Drug Warning. Kansas City, Mo: Marion Merrell Dow Inc; July 1992.
28. Janssen Research Foundation. Med Gram— Important Drug Warning. Titusville, NJ: Janssen Research Foundation; July 3, 1992.